Additionally, the discovery of lung cancer driver genes and their targeted inhibitors, such as epidermal growth factor receptor (EGFR) and ALK receptor tyrosine kinase inhibitors, has achieved remarkable clinical benefits45,46. This evidence concerns the gene EGFR and lung carcinoma.